Ozempic Lawsuit Overview

What Is the Ozempic Lawsuit?

A growing number of lawsuits are being filed against Novo Nordisk (maker of Ozempic, Wegovy, and Rybelsus) and Eli Lilly (maker of Mounjaro and Zepbound) alleging that these popular GLP-1 receptor agonist medications cause severe gastrointestinal injuries that were not adequately disclosed to patients or doctors.

These drugs — originally developed for type 2 diabetes but widely prescribed for weight loss — have become some of the best-selling pharmaceuticals in history. However, thousands of patients report debilitating side effects far beyond what the warning labels describe.

What Injuries Are Linked to GLP-1 Drugs?

The lawsuits allege these medications can cause:

• Gastroparesis (stomach paralysis) — The stomach loses its ability to empty food normally, causing severe nausea, vomiting, bloating, and malnutrition. This condition can be permanent.
• Intestinal obstruction — Blockage of the bowels that may require emergency surgery
• Pancreatitis — Inflammation of the pancreas causing severe abdominal pain, which can be life-threatening
• Gallbladder disease — Including gallstones and cholecystitis requiring surgical removal
• Kidney injury — Acute kidney damage from severe dehydration caused by persistent vomiting
• Cyclic vomiting syndrome — Recurrent episodes of severe vomiting lasting hours or days

Which Drugs Are Involved?

Drug	Manufacturer	Active Ingredient	Approved For
Ozempic	Novo Nordisk	Semaglutide	Type 2 diabetes
Wegovy	Novo Nordisk	Semaglutide	Weight loss
Rybelsus	Novo Nordisk	Semaglutide (oral)	Type 2 diabetes
Mounjaro	Eli Lilly	Tirzepatide	Type 2 diabetes
Zepbound	Eli Lilly	Tirzepatide	Weight loss
Trulicity	Eli Lilly	Dulaglutide	Type 2 diabetes
Saxenda	Novo Nordisk	Liraglutide	Weight loss

What Are Plaintiffs Alleging?

The lawsuits allege that Novo Nordisk and Eli Lilly:

• Knew about the risk of severe gastrointestinal injuries from clinical trial data and post-market reports
• Failed to adequately warn patients and prescribing physicians about the severity and duration of gastroparesis and other injuries
• Used aggressive direct-to-consumer marketing that minimized serious risks
• Labeled gastroparesis symptoms as mere "nausea" on the warning label, understating the true condition
• Profited enormously while patients suffered — Ozempic alone generates over $13 billion annually for Novo Nordisk

Current Status of the Litigation

The Ozempic litigation is consolidated as MDL 3094 in the Eastern District of Pennsylvania.

• Rapidly growing docket with thousands of cases filed
• Bellwether trial selection underway
• No settlement — both defendants are actively contesting the claims
• New cases filed daily as more patients experience delayed-onset side effects
• FDA has updated labels to include gastroparesis warnings, which plaintiffs argue proves the manufacturers knew of the risk

Why You Should Act Now

If you took Ozempic, Wegovy, Mounjaro, or a related medication and experienced serious side effects:

• Statutes of limitations are running — each state has its own filing deadline
• The litigation is in a critical phase where early filers may be best positioned
• Your medical records from during and after treatment are essential evidence

A free case review costs nothing. Find out if your experience with these medications qualifies you for compensation.